Medicus Pharma Ltd. — fact timeline

Medicus Pharma Ltd. shareholders approved Shareholders approved the special resolution authorizing the Board, in its discretion, to effect a consolidation of the Company's common shares, no par value (the "Common Shares") on the basis of a consolidation ratio to be determined by the Board, up to a maximum ratio of 50 pre-consolidation Commo at the 2026-06-03 meeting.

“Shareholders approved the special resolution authorizing the Board, in its discretion, to effect a consolidation of the Company's common shares, no par value (the "Common Shares") on the basis of a consolidation ratio to be determined by the Board, up to a maximum ratio of 50 pre-consolidation Common Shares for every one post-consolidation Common Share, if the Board determines such a consolidation is necessary or desirable, including, without limitation, for the purpose of meeting any applicable stock exchange or regulatory requirements. Shareholder approval of this Proposal 3 required the affirmative vote of at least two-thirds of the votes cast by the shareholders present at the Meeting in person or by proxy: For Against Abstain Broker Non-Votes 26,729,776 2,335,461 N/A 1”

Medicus Pharma Ltd. shareholders approved Shareholders elected all nine of the directors nominated by the Board to serve for one-year terms, until our 2027 annual meeting of shareholders or until their successors are duly elected or appointed, unless they resign, are removed, or become disqualified in accordance with the Articles of Incorpo at the 2026-06-03 meeting.

“Shareholders elected all nine of the directors nominated by the Board to serve for one-year terms, until our 2027 annual meeting of shareholders or until their successors are duly elected or appointed, unless they resign, are removed, or become disqualified in accordance with the Articles of Incorporation of the Company (the "Articles") or the Business Corporations Act (Ontario): Name For Withhold Abstain Broker Non-Votes William L. Ashton 15,181,189 354,284 N/A 13,529,765 Dr. Raza Bokhari 15,068,465 467,008 N/A 13,529,765 Robert J. Ciaruffoli 15,186,431 349,042 N/A 13,529,765 Barry Fishman 15,189,646 345,827 N/A 13,529,765 Dr. Larry Kaiser 15,198,014 337,459 N/A 13,529,765 Patrick Mahaffy 15,193,804 341,669 N/A 13,529,765 Dr. Sara R. May 15,192,642 342,831 N/A 13,529,765 Hon. Cathy McMorris Rodgers 15,178,833 356,640 N/A 13,529,765 Ajay Raju 15,190,298 345,175 N/A 13,529,765”

Medicus Pharma Ltd. shareholders approved Shareholders ratified the appointment of KPMG LLP as the Company's independent registered public accounting firm for the Company's 2026 fiscal year and the authorization of the Company's board of directors to fix the auditors' remuneration and terms of engagement at the 2026-06-03 meeting.

“Shareholders ratified the appointment of KPMG LLP as the Company's independent registered public accounting firm for the Company's 2026 fiscal year and the authorization of the Company's board of directors (the "Board") to fix the auditors' remuneration and terms of engagement: For Withhold Abstain Broker Non-Votes 28,308,860 756,378 N/A 0”

Medicus Pharma Ltd. incurred loan of $10,000,000 with Streeterville Capital, LLC at 5% per annum maturing eighteen months following the date of issuance.

“(i) a Secured Promissory Note A-1 in the original principal amount of $12,864,225 (the "A-1 Note") and (ii) a Secured Promissory Note B in the original principal amount of $10,000,000 (the "B Note" and together with the A-1 Note, the "Notes"). The A-1 Note carries an original issue discount ("OID") of $834,225 and the Company agreed to pay $30,000 to the Lender”

Medicus Pharma Ltd. incurred loan of $12,864,225 with Streeterville Capital, LLC at 8.75% per annum maturing eighteen months following the date of issuance.

“with Streeterville Capital, LLC, (the "Lender") providing for the issuance of two secured promissory notes: (i) a Secured Promissory Note A-1 in the original principal amount of $12,864,225 (the "A-1 Note") and (ii) a Secured Promissory Note B in the original principal amount of $10,000,000 (the "B Note" and together with the A-1 Note, the "Notes"). The A-1 Note”

Medicus Pharma Ltd. received a nasdaq deficiency notice notice regarding market value (rules 5550(b)(2), 5550(b)(1), 5550(b)(3), 5810(c)(3)(C)).

“May 20, 2026, the Company received written notice (the "Notice") from the Listing Qualifications Department of the Nasdaq notifying the Company that it is not in compliance with the minimum Market Value of Listed Securit”

Medicus Pharma Ltd. amended Equity Distribution Agreement with Maxim Group LLC and Yorkville Securities, LLC valued at up to $50,000,000 (effective 2026-04-23).

“the Company and the Agents entered into Amendment No. 1 to the Agreement (the "First Amendment", and together with the Agreement, the "Amended Agreement"), pursuant to which the Company increased the size of the aggregate offering amount from $15,349,674 to up to $50,000,000 (the "ATM Upsize")”

Medicus Pharma Ltd. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).

“April 21, 2026, the Company received written notice (the "Notice") from the Listing Qualifications Department of the Nasdaq Stock Market LLC ("Nasdaq"), notifying the Company that the closing bid price for the Company's”

Medicus Pharma Ltd. issued 4,471,038 of common stock to YA II PN, Ltd. for $3,846,910.

“the Company completed sales of its common shares (the "Common Shares") to Yorkville (collectively, the "SEPA Advances") as disclosed in the table below: Date of Sale Number of Common Shares Approximate Aggregate Consideration December 19, 2025 66,667 $113,647 December 19, 2025 5,432 $9,221 December 29, 2025 41,250 $66,149 December 29, 2025 20,909 $32,451 January 9, 2026 100,000 $150,640 January 15, 2026 33,333 $48,006 January 15, 2026 11,347 $15,960 January 29, 2026 7,100 $8,609 February 10, 2026 175,000 $186,603 February 18, 2026 250,000 $237,200 February 23, 2026 275,000 $302,088 March 5, 2026 700,000 $988,890 March 5, 2026 1,360,000 $1,047,336 March 6, 2026 1,425,000 $640,110 Total 4,471,038 $3,846,910”

Medicus Pharma Ltd. entered into Equity Distribution Agreement with Maxim Group LLC and Yorkville Securities, LLC valued at up to $15,349,674 (effective 2025-12-29).

“On December 29, 2025, Medicus Pharma Ltd. (the "Company") entered into an Equity Distribution Agreement (the "Agreement") with Maxim Group LLC ("Maxim") and Yorkville Securities, LLC ("Yorkville Securities" and together with Maxim, the "Agents") to create an at-the-market equity program.”

Medicus Pharma Ltd. entered into Warrant Inducement Agreement with a certain accredited and institutional holder valued at approximately $5.1 million (effective 2025-12-05).

“On December 5, 2025, Medicus Pharma Ltd. (the "Company") entered into an inducement offer (the "Agreement") with a certain accredited and institutional holder (the "Holder") to exercise existing warrants to purchase up to 2,680,000 of the Company's common shares ("Common Shares") issued on July 14, 2025 at an amended exercise price of $1.92 per Common Share (the "Existing Warrants").”

Medicus Pharma Ltd. issued 680,893 of common stock to YA II PN, Ltd. (Yorkville) for $1,500,905 aggregate.

“the Company completed sales of its common shares (the "Common Shares") to Yorkville (collectively, the "SEPA Advances") as disclosed in the table below: Date of Sale Number of Common Shares Price per share Approximate Aggregate Consideration October 28, 2025 250,000 $2.3760 $594,000 November 5, 2025 83,333 $2.2691 $189,091 November 5, 2025 14,659 $2.1825 $31,993 November 14, 2025 83,375 $2.2374 $186,543 November 14, 2025 4,526 $2.231 $10,098 November 20, 2025 33,333 $2.3423 $78,076 November 20, 2025 31,667 $2.2795 $72,185 November 28, 2025 66,667 $1.9462 $129,747 November 28, 2025 33,333 $1.9400 $64,666 December 4, 2025 33,333 $1.9587 $65,289 December 4, 2025 46,667 $1.6975 $79,217 Total 680,893 - $1,500,905”

Medicus Pharma Ltd. issued up to 4,020,000 Common Shares of warrant to accredited and institutional holder for amended exercise price of $1.92 per Common Share.

“(the "Holder") to exercise existing warrants to purchase up to 2,680,000 of the Company's common shares ("Common Shares") issued on July 14, 2025 at an amended exercise price of $1.92 per Common Share (the "Existing Warrants"). Pursuant to the Agreement, the Holder, upon exercise, will receive new unregistered warrants (the "New Warrants") to purchase up to”

Medicus Pharma Ltd. issued 1,088,048 common shares of common stock to YA II PN, Ltd. (Yorkville) for $2,526,364 aggregate.

“2, 2025 250,000 $2.1884 $547,100 October 8, 2025 125,000 $2.3542 $294,275 October 16, 2025 41,667 $2.2901 $95,422 October 16, 2025 68,363 $2.2795 $155,833 Total 1,088,048 $2,526,364 The Company may cause Yorkville to purchase additional Common Shares under the SEPA from time to time, subject to the satisfaction or waiver of the conditions and limitations set”

Medicus Pharma Ltd. completed an acquisition involving Antev Ltd. for approximately US$3.0 million in cash and 1,603,164 common shares (closed 2025-08-29).

“On August 29, 2025, Medicus Pharma Ltd. ("Medicus" or the "Company") completed (the "Closing") its previously announced acquisition of Antev Ltd. ("Antev") pursuant to that certain definitive securities exchange agreement, dated as of June 29, 2025 (as amended, the "Definitive Agreement"), by and among the Company, Antev and certain securityholders of Antev (the "Antev Vendors"), pursuant to which the Company acquired (the "Transaction") 98.6% of the issued and outstanding shares of Antev for aggregate consideration consisting of approximately US$3.0 million in cash and 1,603,164 common shares of Medicus (the "Consideration Shares").”

Andrew Smith was appointed as Chief Operating Officer at Medicus Pharma Ltd..

“On June 23, 2025, Medicus Pharma Ltd. (the "Company") announced the appointment of Andrew Smith, age 57, to serve as the Company's Chief Operating Officer ("COO").”

Medicus Pharma Ltd. incurred credit facility of $2,500,000 with YA II PN, Ltd. at 8.00% per annum, subject to a potential increase to 18.00% per annum upon the oc maturing February 2, 2026.

“On June 17, 2025, Yorkville purchased and the Company issued a third Debenture in aggregate principal amount of $2,500,000, such amount being the remaining amount available pursuant to the Purchase Agreement, for net proceeds to the Company of $2,250,000”

Medicus Pharma Ltd. engaged KPMG LLP as its auditor.

“On June 4, 2025, in connection with the Company's dismissal of EisnerAmper, the Board approved the engagement of KPMG as its new independent registered public accounting firm to audit the Company's financial statements for the year ending December 31, 2025.”

Medicus Pharma Ltd. dismissed EisnerAmper LLP as its auditor.

“On June 3, 2025, Medicus Pharma Ltd. (the "Company") dismissed EisnerAmper LLP ("EisnerAmper") as the Company's independent registered public accounting firm.”